These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 15197486

  • 1. Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line.
    Mortenson MM, Schlieman MG, Virudachalam S, Bold RJ.
    Cancer Chemother Pharmacol; 2004 Oct; 54(4):343-53. PubMed ID: 15197486
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study.
    Davies AM, Ruel C, Lara PN, Lau DH, Gumerlock PH, Bold R, Shibata S, Lenz HJ, Schenkein DP, Gandara DR.
    J Thorac Oncol; 2008 Jan; 3(1):68-74. PubMed ID: 18166843
    [Abstract] [Full Text] [Related]

  • 5. The potential role of bortezomib in combination with chemotherapy and radiation in non-small-cell lung cancer.
    Edelman MJ.
    Clin Lung Cancer; 2005 Oct; 7 Suppl 2():S64-6. PubMed ID: 16250930
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Combined proteasome and histone deacetylase inhibition in non-small cell lung cancer.
    Denlinger CE, Keller MD, Mayo MW, Broad RM, Jones DR.
    J Thorac Cardiovasc Surg; 2004 Apr; 127(4):1078-86. PubMed ID: 15052205
    [Abstract] [Full Text] [Related]

  • 9. Proteasome inhibition with bortezomib enhances activity of topoisomerase I-targeting drugs by NF-kappaB-independent mechanisms.
    Takigawa N, Vaziri SA, Grabowski DR, Chikamori K, Rybicki LR, Bukowski RM, Ganapathi MK, Ganapathi R, Mekhail T.
    Anticancer Res; 2006 Apr; 26(3A):1869-76. PubMed ID: 16827119
    [Abstract] [Full Text] [Related]

  • 10. Bortezomib induces schedule-dependent modulation of gemcitabine pharmacokinetics and pharmacodynamics in non-small cell lung cancer and blood mononuclear cells.
    Ceresa C, Giovannetti E, Voortman J, Laan AC, Honeywell R, Giaccone G, Peters GJ.
    Mol Cancer Ther; 2009 May; 8(5):1026-36. PubMed ID: 19383850
    [Abstract] [Full Text] [Related]

  • 11. Preclinical data with bortezomib in lung cancer.
    Schenkein DP.
    Clin Lung Cancer; 2005 Oct; 7 Suppl 2():S49-55. PubMed ID: 16250927
    [Abstract] [Full Text] [Related]

  • 12. Sequencing bortezomib with chemotherapy and targeted agents.
    Adjei AA.
    Clin Lung Cancer; 2005 Oct; 7 Suppl 2():S56-8. PubMed ID: 16250928
    [Abstract] [Full Text] [Related]

  • 13. The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo.
    Kamat AM, Karashima T, Davis DW, Lashinger L, Bar-Eli M, Millikan R, Shen Y, Dinney CP, McConkey DJ.
    Mol Cancer Ther; 2004 Mar; 3(3):279-90. PubMed ID: 15026548
    [Abstract] [Full Text] [Related]

  • 14. Use of proteasome inhibition in the treatment of lung cancer.
    Schenkein DP.
    Clin Lung Cancer; 2004 Dec; 6 Suppl 2():S89-96. PubMed ID: 15638966
    [Abstract] [Full Text] [Related]

  • 15. Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial.
    Lara PN, Longmate J, Reckamp K, Gitlitz B, Argiris A, Ramalingam S, Belani CP, Mack PC, Lau DH, Koczywas M, Wright JJ, Shepherd FA, Leighl N, Gandara DR.
    Clin Lung Cancer; 2011 Jan; 12(1):33-7. PubMed ID: 21273177
    [Abstract] [Full Text] [Related]

  • 16. Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report.
    Voortman J, Giaccone G.
    BMC Cancer; 2006 May 11; 6():129. PubMed ID: 16689991
    [Abstract] [Full Text] [Related]

  • 17. [Proteasome inhibitors].
    Alexandre J.
    Rev Med Interne; 2005 Oct 11; 26(10):812-5. PubMed ID: 16129520
    [Abstract] [Full Text] [Related]

  • 18. Effects and mechanisms of the combination of suberoylanilide hydroxamic acid and bortezomib on the anticancer property of gemcitabine in pancreatic cancer.
    Lee JK, Ryu JK, Yang KY, Woo SM, Park JK, Yoon WJ, Lee SH, Jeong KS, Kim YT, Yoon YB.
    Pancreas; 2011 Aug 11; 40(6):966-73. PubMed ID: 21487323
    [Abstract] [Full Text] [Related]

  • 19. Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma.
    Alinari L, White VL, Earl CT, Ryan TP, Johnston JS, Dalton JT, Ferketich AK, Lai R, Lucas DM, Porcu P, Blum KA, Byrd JC, Baiocchi RA.
    MAbs; 2009 Aug 11; 1(1):31-40. PubMed ID: 20046572
    [Abstract] [Full Text] [Related]

  • 20. [Proteasome inhibitor].
    Yamamura M, Hirai T, Yamaguchi Y.
    Nihon Rinsho; 2010 Jun 11; 68(6):1079-84. PubMed ID: 20535959
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.